Topical imiquimod in combination with brachytherapy for unresectable cutaneous melanoma scalp metastases

• Jennifer E. Yeh, MD, PhD,
• Marilyn T. Wan, MBChB,
• Allireza Alloo, MD,
• Nageatte Ibrahim, MD,
• Ivan Buzurovic, PhD,
• Jeffrey M. Cohen, MD,
• Patrick A. Ott, MD, PhD,
• Alvaro C. Laga, MD,
• Phillip M. Devlin, MD,
• Jennifer Y. Lin, MD

Affiliations

Jennifer E. Yeh, MD, PhD

Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts; Department of Dermatology, Stanford University School of Medicine, Redwood City, California

Marilyn T. Wan, MBChB

Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts; Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Allireza Alloo, MD

Department of Dermatology, Northwell Health, Lake Success, New York

Nageatte Ibrahim, MD

Dana Farber Cancer Institute, Melanoma Program, Boston, Massachusetts; Department of Oncology, Global Clinical Development, Merck & Co, Kenilworth, New Jersey

Ivan Buzurovic, PhD

Department of Radiation Oncology, Brigham & Women’s/Dana Farber Cancer Institute Cancer Center, Boston, Massachusetts

Jeffrey M. Cohen, MD

Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts; Department of Dermatology, Yale School of Medicine, New Haven, Connecticut

Patrick A. Ott, MD, PhD

Dana Farber Cancer Institute, Melanoma Program, Boston, Massachusetts

Alvaro C. Laga, MD

Dana Farber Cancer Institute, Melanoma Program, Boston, Massachusetts

Phillip M. Devlin, MD

Department of Radiation Oncology, Brigham & Women’s/Dana Farber Cancer Institute Cancer Center, Boston, Massachusetts

Jennifer Y. Lin, MD

Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts; Dana Farber Cancer Institute, Melanoma Program, Boston, Massachusetts; Correspondence to: Jennifer Y. Lin, MD, Department of Dermatology, Brigham and Women’s Hospital, Emmanuel College, Alumnae Hall, 41 Ave Louis Pasteur, Boston, MA 02115.